Ashland Opens New Center of Excellence in Hyderabad
News Apr 09, 2014
Ashland Specialty Ingredients held a grand opening ceremony for the opening of a new pharmaceutical center of excellence in Hyderabad, India.
This is the ninth center of excellence that Ashland Specialty Ingredients has opened, and it joins Ashland’s global network of three dozen research and development and technical centers.
The facility specializes in oral solid-dosage form research and expands Ashland’s global reach, pharmaceutical research and footprint outside of North America.
“A key Ashland commitment is to be close to our customers,” said Luis Fernandez-Moreno, president, Ashland Specialty Ingredients, during the grand opening ceremony. “Investments in state of-the-art facilities allow us to drive growth and deliver innovation where our customers are located. This facility provides our customers in India and throughout the region with a center of excellence to develop and enhance their pharmaceutical formulations.”
“Research and development dedicated to optimal yields and lower variability in oral solid-dosage forms is essential to the future success of the pharmaceutical manufacturing industry,” said Jim Mish, group vice president, Consumer Specialties, Ashland Specialty Ingredients.
Mish continued, “Emerging manufacturing processes, such as continuous manufacturing by spray drying or hot-melt extrusion, is one component of this equation. Excipients science is another. At our new center of excellence, we bring together our expertise in process technology and our knowledge in materials science to further support the quality, safety and efficiency of oral solid-dosage forms.”
“The Ashland Pharmaceutical Specialties research and development team takes a very customer-focused approach to our business. Roughly 70 percent of our current R&D projects involve working directly with our customers on a collaborative basis,” explained Tom Dürig, senior director, global pharmaceutical R&D, Consumer Specialties, Ashland Specialty Ingredients.
Dürig continued, “We provide customized training on product applications to our customers. Additionally, our team can provide technical assistance for specific requests from customers. Superior technical service forms an important part of our offering and distinguishes Ashland from our competitors. The products we manufacture are supported by a global network of research and application scientists and technically trained salespeople.”
With close to two billion consumers in the region, India and Southeast Asia are home to one of the fastest-growing populations in the world. Ashland Specialty Ingredients offers comprehensive and innovative solutions for today’s global pharmaceutical and nutraceutical industries.
Having served these markets since the 1950s, Ashland offers an unparalleled excipient portfolio and a global research and development team focused on all of the major formulation trends.
The opening of this pharmaceutical center of excellence in Hyderabad is part of the company’s commitment to serving this need and reinforcing its market leadership as a specialty chemical company.
This center of excellence expands Ashland’s global network of R&D and technical support facilities dedicated to the advancement of consumer products. It’s another major investment following the opening of personal care center of excellence in Mumbai, India, in 2012. Ashland Specialty Ingredients has nine centers of excellence around the world.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018